Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: In vivo evidence of involvement of P-glycoprotein in risperidone disposition

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 1, 2005, Pages 43-51

  Nakagami, Taku ^a   Yasui Furukori, Norio ^a   Saito, Manabu ^a   Tateishi, Tomonori ^a   Kaneo, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLYCOPROTEIN P; PALIPERIDONE; PLACEBO; PROLACTIN; RISPERIDONE; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION LOSS; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; MENTAL DETERIORATION; METHODOLOGY; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SOMNOLENCE; STATISTICAL SIGNIFICANCE; THORAX PAIN; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; GENOTYPE; HALF-LIFE; HUMANS; IMMUNOENZYME TECHNIQUES; ISOXAZOLES; JAPAN; MALE; P-GLYCOPROTEIN; PATIENT SELECTION; PROLACTIN; PYRIMIDINES; RISPERIDONE; STATISTICS; VERAPAMIL;

EID: 21844473814     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.03.009     Document Type: Article

References (49)

1. A. Ayrton, P. Morgan Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 31 2001 469 497
2. R.B. Kim Transporters and xenobiotic disposition Toxicology 181-2 2002 291 297
3. J.H. Hochman, M. Yamazaki, T. Ohe, J.H. Lin Evaluation of drug interactions with P-glycoprotein in drug discovery in vitro assessment of the potential for drug-drug interactions with P-glycoprotein Curr Drug Metab 3 2002 257 273
4. J.H. Lin, M. Yamazaki Role of P-glycoprotein in pharmacokinetics clinical implications Clin Pharmacokinet 42 2003 59 98
5. M.F. Fromm Importance of P-glycoprotein for drug disposition in humans Eur J Clin Invest 33 Suppl 2 2003 6 9
6. J. Sun, Z.G. He, G. Cheng, S.J. Wang, X.H. Hao, M.J. Zou Multidrug resistance P-glycoprotein crucial significance in drug disposition and interaction Med Sci Monit 10 2004 RA5 RA14
7. H. Suzuki, Y. Sugiyama Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine Eur J Pharm Sci 12 2000 3 12
8. M.F. Fromm P-glycoprotein a defense mechanism limiting oral bioavailability and CNS accumulation of drugs Int J Clin Pharmacol Ther 38 2000 69 74
9. K.I. Inui, S. Masuda, H. Saito Cellular and molecular aspects of drug transport in the kidney Kidney Int 58 2000 944 958
10. W. Lee, R.B. Kim Transporters and renal drug elimination Annu Rev Pharmacol Toxicol 44 2004 137 166
11. G.J. Hooiveld, J.E. van Montfoort, D.K. Meijer, M. Muller Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport Eur J Pharm Sci 12 2001 525 543
12. P.A.J. Jansen, C.J.E. Niemegeers, F. Awouters, K.H.L. Schellekens, A.A.H.P. Megens, T.F. Meert Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties J Pharmacol Exp Ther 244 1988 685 693
13. J.E. Leysen, W. Gommeren, A. Eeens, D. de Chaffoy de Courdells, J.C. Stoof Biochemical profiles of risperidone, a new antipsychotic J Pharmacol Exp Ther 244 1988 685 693
14. A. Claus, J. Bollen, H. De Cuyper, M. Eneman, M. Malfroid, J. Peuskens Risperidone versus haloperidol in the treatment of chromic schizophrenia inpatians multicenter double-blind comparative study Acta Psychiatr Scand 85 1992 295 305
15. G. Chouinard, B. Jones, G. Remington, D. Bloom, D. Addington, G.W. Macewan A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenia patients J Clin Psychopharmacol 13 1993 25 40
16. D.W. Boulton, C.L. DeVane, H.L. Liston, J.S. Markowitz In vitro P-glycoprotein affinity for atypical and conventional antipsychotics Life Sci 71 2002 163 169
17. N. Yasui-Furukori, K. Mihara, T. Takahata, A. Suzuki, T. Nakagami, R. De Vries Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone lack of impact of MDR-1 genotypes Br J Clin Pharmacol 57 2004 569 575
18. D. Belpomme, S. Gauthier, E. Pujade-Lauraine, T. Facchini, M.J. Goudier, I. Krakowski Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma Ann Oncol 11 2000 1471 1476
19. M.B. Molento, A. Lifschitz, J. Sallovitz, C. Lanusse, R. Prichard Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep Parasitol Res 92 2004 121 127
20. O. Lingjaerde, U.G. Ahlfors, P. Bech, S.J. Dencker, K. Elgen The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients Acta Psychiatr Scand Suppl 334 1987 1 100
21. M. Heim, U.A. Meyer Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification Lancet 336 1990 529 532
22. V.M. Steen, O.A. Andreassen, A.K. Daly, T. Tefre, A.L. Børresen, J.R. Idle Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology Pharmacogenetics 5 1995 215 223
23. I. Johansson, M. Oscarson, Q.Y. Yue, L. Bertilsson, F. Sjöqvist, M. Ingelman-Sundberg Genetic analysis of the Chinese cytochrome P450D locus characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation Mol Pharmacol 46 1994 452 459
24. T. Kubota, Y. Yamaura, N. Ohkawa, H. Hara, K. Chiba Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes Br J Clin Pharmacol 50 2000 31 34
25. N. Yasui-Furukori, T. Uno, K. Sugawara, T. Tateishi Different effects of three transporting inhibitors, verapamil, cimetidine and probenecid on fexofenadine pharmacokinetics Clin Pharmacol Ther 77 2005 17 23
26. C. Tannergren, N. Petri, L. Knutson, M. Hedeland, U. Bondesson, H. Lennernas Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine Clin Pharmacol Ther 74 2003 423 436
27. X.J. Zhao, T. Ishizaki A further interaction study of quinine with clinically important drugs by human liver microsomes determinations of inhibition constant (Ki) and type of inhibition Eur J Drug Metab Pharmacokinet 24 1999 272 278
28. B. Ma, T. Prueksaritanont, J.H. Lin Drug interactions with calcium channel blockers possible involvement of metabolite-intermediate complexation with CYP3A Drug Metab Dispos 28 2000 125 130
29. Y.H. Wang, D.R. Jones, S.D. Hall Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites Drug Metab Dispos 32 2004 259 266
30. J. Fang, M. Bourin, G.B. Baker Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 Naunyn Schmiedebergs Arch Pharmacol 359 1999 147 151
31. N. Yasui-Furukori, M. Hidestrand, E. Spina, G. Facciola, M.G. Scordo, G. Tybring Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes Drug Metab Dispos 29 2001 1263 1268
32. M. Cvetkovic, B. Leake, M.F. Fromm, G.R. Wilkinson, R.B. Kim OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metab Dispos 27 1999 866 871
33. E. Snoeck, A. Van Peer, M. Sack, M. Horton, G. Mannens, R. Woestenborghs Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man Psychopharmacology 122 1995 223 229
34. C.J. Matheny, M.W. Lamb, K.R. Brouwer, G.M. Pollack Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation Pharmacotherapy 21 2001 778 796
35. M.G. Scordo, E. Spina, G. Facciolà, A. Avenoso, I. Johansson, M.L. Dahl Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone Psychopharmacology 147 1999 300 305
36. H.K. Roh, C.E. Kim, W.G. Chung, C.S. Park, J.O. Svensson, L. Bertilsson Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients Eur J Clin Pharmacol 57 2001 671 675
37. N. Yasui-Furukori, K. Mihara, T. Kondo, T. Kubota, T. Iga, Y. Takarada Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia J Clin Pharmacol 43 2003 122 127
38. K. Mihara, T. Kondo, N. Yasui-Furukori, A. Suzuki, M. Ishida, S. Ono Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia Ther Drug Monit 25 2003 287 293
39. M.L. Huang, A. Van Peer, R. Woestenborghs, R. De Coster, J. Heykants, A.A.I. Jansen Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects Clin Pharmacol Ther 54 1993 257 268
40. C. Cordon-Cardo, J.P. O'Brien, D. Casals, L. Rittman-Grauer, J.L. Biedler, M.R. Melamed Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites Proc Natl Acad Sci U S A 86 1989 695 698
41. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu Rev Pharmacol Toxicol 39 1999 361 398
42. L.Z. Benet, T. Izumi, Y. Zhang, J.A. Silverman, V.J. Wacher Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery J Control Release 62 1999 25 31
43. V.V. Rao, J.L. Dahlheimer, M.E. Bardgett, A.Z. Snyder, R.A. Finch, A.C. Sartorelli Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal- fluid drug-permeability barrier Proc Natl Acad Sci U S A 96 1999 3900 3905
44. A.J. Sadeque, C. Wandel, H. He, S. Shah, A.J. Wood Increased drug delivery to the brain by P-glycoprotein inhibition Clin Pharmacol Ther 68 2000 231 237
45. J. Tauscher, C. Jones, G. Remington, R.B. Zipursky, S. Kapur Significant dissociation of brain and plasma kinetics with antipsychotics Mol Psychiatry 7 2002 317 321
46. A. Takano, T. Suhara, Y. Ikoma, F. Yasuno, J. Maeda, T. Ichimiya Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics Int J Neuropsychopharmacol 7 2004 19 26
47. H. Potschka, W. Loscher In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats Epilepsia 42 2001 1231 1240
48. H. Potschka, M. Fedrowitz, W. Loscher P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier evidence from microdialysis experiments in rats Neurosci Lett 327 2002 173 176
49. M. Knoepfelmacher, S.M. Villares, W. Nicolau, O.O. Germek, A.C. Lerario, B.L. Wajchenberg Calcium and prolactin secretion in humans effects of the channel blocker, verapamil, in the spontaneous and drug-induced hyperprolactinemia Horm Metab Res 26 1994 481 485